Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$1.9B
23M shares
52-week range
$78.65 – $118.01
8% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
www.lemaitre.comNo one on the platform currently holds LMAT.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 138,502 | $15.1M |
| Bridgewater Associatesas of 2024-12-31 | 2,353 | $216.8K |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-08-20 | $0.2500 | 2026-09-03 |
| 2026-05-21 | $0.2500 | 2026-06-04 |
| 2026-03-12 | $0.2500 | 2026-03-26 |
| 2025-11-20 | $0.2000 | 2025-12-04 |
| 2025-08-21 | $0.2000 | 2025-09-04 |
| 2025-05-15 | $0.2000 | 2025-05-29 |
| 2025-03-13 | $0.2000 | 2025-03-27 |
| 2024-11-21 | $0.1600 | 2024-12-05 |
| 2024-08-15 | $0.1600 | 2024-08-29 |
| 2024-05-15 | $0.1600 | 2024-05-30 |
No one on the platform has traded LMAT yet.
| 2024-03-13 | $0.1600 | 2024-03-28 |
| 2023-11-15 | $0.1400 | 2023-11-30 |
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$HUMA Any thoughts on $LMAT earnings release? Any predictive value regarding upcoming HUMA earnings?? $LMAT has more than $300 milli in cash and have grown by acquisition 🤔
View on StockTwits ↗$LMAT -24% 📉 Herb Greenberg short report
View on StockTwits ↗$LMAT is facing a new test after the short report. The debate now is whether growth is being driven by real business momentum or just pricing. Upcoming results should give more clarity on the underlying demand.
View on StockTwits ↗$LMAT - LeMaitre Vascular Inc - 10Q - Updated Risk Factors LMAT highlights heightened regulatory and product-quality risk: approvals can be withdrawn, global recalls and product liability suits could be costly and damaging, and an FDA warning letter plus new observations at the Artegraft facility may lead to further inspections, enforcement, and financial or reputational impact. #MedicalDevices #RegulatoryRisk #ProductQuality #FDACompliance #LegalLiability 🟢 Added 🟠 Removed https://d-risk.ai/LMAT/10-Q/2026-08-05
View on StockTwits ↗Vector Intelligence (VI) is an algorithm designed to predict potential outsized intraday moves. VI will select up to 4 stocks per day. Today's VI stocks: $LMAT, $PRCT, $SHOP.
View on StockTwits ↗$LMAT (-16.8% pre) LeMaitre (NASDAQ:LMAT) Misses Q2 CY2026 Revenue Estimates, Stock Drops https://ooc.bz/l/110024
View on StockTwits ↗$LMAT reported 0.74 EPS and 70.38 revenue for Q2. http://www.estimize.com/intro/lmat?chart=historical&metric_name=eps&utm_content=LMAT&utm_
View on StockTwits ↗https://www.marketbeat.com/earnings/reports/2026-8-4-lemaitre-vascular-inc-stock/ $LMAT LeMaitre Vascular Earnings Transcript
View on StockTwits ↗$LMAT Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.75 up 22.95% YoY • Reported revenue of $70.38M up 9.57% YoY • LeMaitre Vascular, Inc. provides full year 2026 guidance of $274.3mm - $278.3mm in sales, a 72.4% gross margin, and EPS in the range of $2.84 - $2.94 per share.
View on StockTwits ↗$LMAT https://www.globenewswire.com/news-release/2026/08/04/3338797/10507/en/lemaitre-q2-2026-financial-results.html
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $277M | +11.8% | $2.90 | $2.84–$2.95 | 28.3× | 5 |
| 2027 | $303M | +9.5% | $3.20 | $3.17–$3.23 | 25.6× | 6 |
| 2028 | $330M | +8.7% | $3.41 | $3.23–$3.54 | 24.0× | 3 |
| 2029 | $351M | +6.5% | $0.00 | $0.00–$0.00 | — | 0 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | $0.81 | $0.74 | -8.3% |
| 2026-05-05 | $0.66 | $0.68 | +3.0% |
| 2026-02-25 | $0.67 | $0.68 | +1.5% |
| 2025-11-06 | $0.56 | $0.62 | +9.9% |
| 2025-08-05 | $0.57 | $0.60 | +5.3% |
| 2025-05-01 | $0.50 | $0.48 | -4.0% |
| 2025-02-27 | $0.49 | $0.49 | +0.0% |
| 2024-10-31 | $0.44 |
| $0.49 |
| +11.4% |
| $4.1B |
| — |
| INSPInspire Medical Systems, Inc. | $58.20 | -0.14% | $1.7B | — |
| NHCNational HealthCare Corporation | $219.84 | -0.81% | $3.4B | — |
Source: Financial Modeling Prep · peers by sector/industry